ClinicalTrials.gg
CompletedNCT01431976Updated Mar 8, 2017Results posted

Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents

A Phase 3 interventional study of Lamictal in Epilepsy, sponsored by GlaxoSmithKline. Completed at 14 sites in 2 countries. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
2 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.

Enrollment
34th of 36
20 · median 76
Started
2011
with 2 others
Phase 3
12 of 36
none open now
Registered
24th of 36
by date
Lead sponsor
19 of 36
GlaxoSmithKline

Among the 36 studies testing lamotrigine in Epilepsy, this one is the 34th largest by enrollment, is one of 3 that started in 2011, is one of 12 in phase 3, and was the 24th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:

All 2 open studies →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 2 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing lamotrigine in Epilepsy, or all of them as a file.
02

Study summary

This is a multi-center, uncontrolled, open-label study to evaluate the efficacy and safety of lamotrigine monotherapy on newly diagnosed typical absence seizure in children and adolescents in Japan and South Korea.

The study period is composed the baseline, fixed escalation phase, escalation phase, maintenance phase, taper phase, and post study examination. During the fixed escalation phase, the investigational product is administered at 0.3 mg/kg/day for 2 weeks (Week 1 to 2), followed by 0.6 mg/kg/day for 2 weeks (Week 3 to 4). Subjects thereafter visit the clinic once every 1 to 2 weeks during the escalation phase to increase the dose by 0.6 mg/kg/day up to a maximum of 10.2 mg/kg/day or 400 mg/day (whichever was less) until patients are confirmed to be seizure-free by HV tests for clinical signs. After seizure free is confirmed by HV-clinical signs, the dose is increased by one level and HV-EEG (electroencephalography) test (first test) is assessed at the next visit. If seizure free is observed by HV-EEG, the same dose is administered. Thereafter, HV-EEG (second test) is assessed at the next visit and if seizure free is confirmed again, the subjects enter the 12-week maintenance phase. During the maintenance phase, patients visit the clinic once every 4 weeks. The dose can be adjusted as necessary within the range of 1.2 to 10.2 mg/kg/day or 400 mg/day (whichever was less) taking into account the status of seizures and the safety. The investigational product is administered once daily (in the evening). However, if the number of tablets is large, twice-daily administration (in the morning and evening) is also allowed. After the completion of maintenance phase, subjects who have responded to lamotrigine without tolerability issues are eligible to enter the extension phase of the study if clinically indicated.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Target disease: Subjects with newly diagnosed and untreated typical absence seizure which is classifiable by the International Classification of Seizures.
  2. Diagnosis of typical absence seizures is established by at least one of two 4-minute hyperventilation tests as supported by clinical signs and EEG findings.

    The following criteria will be used to define a typical absence seizure on the EEG: a discharge of generalized spike-and-wave or multiple spike-and-wave activity lasting ≥3 seconds during the awake state. The frequency of the spike-and-wave should be between 2.5-4.5 Hz.

  3. Age (at the time of obtaining consent):

    • 2 to 15 years of age in Japan
    • 2 to 12 years of age in South Korea
  4. Subjects must weigh at least 7 kg
  5. Outpatients
  6. Parent/guardian must have given written . Subjects who are intellectually able to understand the concepts and procedures of the protocol must give assent by also signing the consent.
  7. Gender: Male or female
  8. \<450 millisecond (msec) or \<480msec for subjects with Bundle Branch Block - values based on either single values or triplicate ECG averaged QTc values obtained over a brief recording period.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with partial seizure or generalized seizures other than typical absence.
  2. Subjects with a history of rash associated with other treatment.
  3. Subjects with any chronic cardiac, renal, or hepatic medical condition. Any patient with these conditions will be excluded from the study even if these conditions are being controlled with chronic therapy.
  4. Subjects with an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or with any unstable physical symptoms likely to require hospitalization during participation in the study.
  5. Subjects with a psychiatric disorder requiring medication, or who had psychiatric conditions in the past that was both judged to be severe and required hospitalization.
  6. Subjects with an acute or progressive neurological disorder or an organic disease.
  7. Subjects with currently taking any psychoactive drugs to treat hyperactivity disorder or attention deficit disorder.
  8. Subjects with an unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  9. Female subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study.
  10. Children in foster care: A child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. This can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or who has an appointed legal guardian.
  11. Subjects taking inducers of lamotrigine glucuronidation (i.e., rifampicin, lopinavir/ritonavir), atazanavir/ritonavir, risperidone, oral or hormone drug which includes estrogen.
  12. Subjects having participated in other clinical study in the past 3 months before the start of product.
  13. Subjects who have active suicidal plan/intent or have had active suicidal thoughts in the past 3 months before the start of investigational product or who have history of suicide attempt in the last 1 year before the start of investigational product or more than 1 lifetime suicide attempt.
  14. Subjects whom the investigator (or subinvestigator) considers ineligible for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Lamotrigine

    No comparison

    Drug: Lamictal

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP)

    EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes using a pin-wheel provided to them.

    Time frame: Week 12 of the Maintenance Phase (up to Study Week 50)

Secondary outcomes

  1. Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Two Consecutive Visits in the Escalation Phase (EP)

    EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them.

    Time frame: Up to Study Week 49

  2. Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Dose During the Escalation Phase

    HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Escalation Phase, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).

    Time frame: Up to Study Week 49

  3. Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs During Week 4 and Week 8 of the Maintenance Phase

    HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Maintenace Phase, HV-clinical signs were assessed at Visit 1 (Week 4) and Visit 2 (Week 4).

    Time frame: Week 4 and Week 8 of the Maintenance Phase (up to Study Weeks 42 and 46, respectively)

  4. Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Each Assessment Point in the Extension Phase (ExP)

    EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).

    Time frame: Extension Week 12 (Extension Visit 1 [Ext-V1]), every 24 weeks after Ext-V1 and until withdrawal

  5. Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Assessment Point in the Extension Phase (ExP)

    HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the ExP, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).

    Time frame: Extension Week 24 (Extension Visit 2 [Ext-V2], every 24 weeks after the Ext-V2 and until withdrawal

  6. Number of Days With Seizure Episodes Per Week in the Main Study Phase (Fixed Escalation Phase [FEP], Escalation Phase [EP], Maintenance Phase [MP]), and FEP+EP+MP)

    Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title)

    Time frame: Up to Study Week 50

  7. Number of Days With Seizure Episodes Per Week in the Extension Phase (ExP) Overall

    Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided.

    Time frame: Extension Week 12 (Extension Visit 1 [Ext-V1], every 12 week after Ext-V1 and until withdrawal

07

Results

Posted Aug 27, 2014

Participant flow

Participants with newly diagnosed and untreated typical absence seizure; aged 2-15 years in Japan, 2-12 years in South Korea at the time of obtaining consent; weighing at least 7 kilograms (kg); without partial seizure or generalized seizures other than typical absence; and without a history of rash associated with other treatment were enrolled.

Participant flow — Overall Study
MilestoneLamotrigine
Started20
Completed6
Not completed14
Withdrew: Adverse event6
Withdrew: Lack of efficacy2
Withdrew: Met protocol-defined stopping criteria4
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP)

EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes using a pin-wheel provided to them.

Time frame:
Week 12 of the Maintenance Phase (up to Study Week 50)
Reported as:
Number · Participants
Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP)
ParticipantsLamotrigine
Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP)7
Statistical analysis
  • Lamotrigine · Percentage of participants: 35.0 · 95% CI 15.39 to 59.22
SecondaryNumber of Participants Who Were Seizure Free as Confirmed by HV-EEG at Two Consecutive Visits in the Escalation Phase (EP)

EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them.

Time frame:
Up to Study Week 49
Reported as:
Number · Participants
Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Two Consecutive Visits in the Escalation Phase (EP)
ParticipantsLamotrigine
Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Two Consecutive Visits in the Escalation Phase (EP)8
SecondaryNumber of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Dose During the Escalation Phase

HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Escalation Phase, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).

Time frame:
Up to Study Week 49
Reported as:
Number · Participants
Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Dose During the Escalation Phase
ParticipantsLamotrigine
0.6 mg/kg, n=171
1.2 mg/kg, n=171
1.8 mg/kg, n=162
2.4 mg/kg, n=162
3.0 mg/kg, n=162
3.6 mg/kg, n=151
4.2 mg/kg, n=150
4.8 mg/kg, n=144
5.4 mg/kg, n=141
6.0 mg/kg, n=111
6.6 mg/kg, n=110
7.2 mg/kg, n=93
7.8 mg/kg, n=90
8.4 mg/kg, n=62
9.0 mg/kg, n=61
9.6 mg/kg, n=11
SecondaryNumber of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs During Week 4 and Week 8 of the Maintenance Phase

HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the Maintenace Phase, HV-clinical signs were assessed at Visit 1 (Week 4) and Visit 2 (Week 4).

Time frame:
Week 4 and Week 8 of the Maintenance Phase (up to Study Weeks 42 and 46, respectively)
Reported as:
Number · Participants
Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs During Week 4 and Week 8 of the Maintenance Phase
ParticipantsLamotrigine
Week 47
Week 87
SecondaryNumber of Participants Who Were Seizure Free as Confirmed by HV-EEG at Each Assessment Point in the Extension Phase (ExP)

EEG is a diagnostic test for epilepsy. The EEG machine records the brain's electrical activity as a series of waveforms. HV is an activation technique used to provoke seizures during an EEG recording. An approximately 30-minute EEG with HV was performed on participants in a supine position. In the HV test, participants breathed through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute ) for 4 continuous minutes using a pin-wheel provided to them. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).

Time frame:
Extension Week 12 (Extension Visit 1 [Ext-V1]), every 24 weeks after Ext-V1 and until withdrawal
Reported as:
Number · Participants
Number of Participants Who Were Seizure Free as Confirmed by HV-EEG at Each Assessment Point in the Extension Phase (ExP)
ParticipantsLamotrigine
Extension Week 12, n=76 ± 1.568
Extension Week 36, n=75 ± 2.114
Extension Week 60, n=76 ± 0.161
Extension Week 84, n=66 ± 2.197
Extension Week 108, n=66
Extension Week 132, n=66
Extension Week 156, n=22
SecondaryNumber of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Assessment Point in the Extension Phase (ExP)

HV is an activation technique used to provoke seizures. Participants were instructed to breathe through their mouths deeply and rapidly (at a rate of approximately 20-25 breaths/minute) for 4 continuous minutes while sitting using a pin-wheel and were observed for clinical signs of seizures like impairment of consciousness; staring; eye enrollment; eye blinking; chewing movements; hand movement; other automatisms; atonic, tonic, clonic components; autonomic components; or any other signs. During the ExP, HV-clinical signs were assessed to confirm a status of seizure free. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title).

Time frame:
Extension Week 24 (Extension Visit 2 [Ext-V2], every 24 weeks after the Ext-V2 and until withdrawal
Reported as:
Number · Participants
Number of Participants Who Were Seizure Free as Confirmed by HV-clinical Signs at Each Assessment Point in the Extension Phase (ExP)
ParticipantsLamotrigine
Extension Week 24, n=75
Extension Week 48, n=76
Extension Week 72, n=75
Extension Week 96, n=66
Extension Week 120, n=65
Extension Week 144, n=42
Extension Week 168, n=11
SecondaryNumber of Days With Seizure Episodes Per Week in the Main Study Phase (Fixed Escalation Phase [FEP], Escalation Phase [EP], Maintenance Phase [MP]), and FEP+EP+MP)

Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided. Only participants data available at the analysis time point were analyzed (represented as n=X, X, X in category title)

Time frame:
Up to Study Week 50
Reported as:
Mean · Days
Number of Days With Seizure Episodes Per Week in the Main Study Phase (Fixed Escalation Phase [FEP], Escalation Phase [EP], Maintenance Phase [MP]), and FEP+EP+MP)
DaysLamotrigine
Fixed Escalation Phase, n=204.93 ± 1.488
Escalation Phase, n=172.60 ± 2.060
Maintenance Phase, n=80.06 ± 0.161
FEP+EP+MP, n=202.98 ± 1.976
SecondaryNumber of Days With Seizure Episodes Per Week in the Extension Phase (ExP) Overall

Participants were asked to record the seizure codes, seizure duration, and their physical condition in a diary provided.

Time frame:
Extension Week 12 (Extension Visit 1 [Ext-V1], every 12 week after Ext-V1 and until withdrawal
Reported as:
Mean · Days
Number of Days With Seizure Episodes Per Week in the Extension Phase (ExP) Overall
DaysLamotrigine
Number of Days With Seizure Episodes Per Week in the Extension Phase (ExP) Overall0.03 ± 0.048

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from study medication start until the end of treatment (up to Study Week 50) (EP, MP, and ExP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lamotrigine—0/20 (0%)17/20 (85%)
Most frequent other events
Showing 10 of 51
Most frequent other events
EventLamotrigine
NasopharyngitisInfections and infestations7/20
RashSkin and subcutaneous tissue disorders6/20
BronchitisInfections and infestations5/20
InfluenzaInfections and infestations5/20
HeadacheNervous system disorders4/20
Upper respiratory tract infectionInfections and infestations3/20
Arthropod stingInjury, poisoning and procedural complications3/20
PharyngitisInfections and infestations2/20
VaricellaInfections and infestations2/20
ConjunctivitisInfections and infestations2/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lamotrigine
Mean7.7 ± 1.95
Sex: Female, Male
Sex: Female, Male(Participants)Lamotrigine
Female13
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lamotrigine
East Asian Heritage3
Japanese Heritage16
South East Asian Heritage1
08

Study locations

14 sites
  • GSK Investigational Site
    Aichi, 453-8511, Japan
  • GSK Investigational Site
    Ehime, 790-8524, Japan
  • GSK Investigational Site
    Ehime, 791-0295, Japan
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Hiroshima, 730-8518, Japan
  • GSK Investigational Site
    Hokkaido, 006-0041, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Kanagawa, 232-8555, Japan
  • GSK Investigational Site
    Niigata, 950-2085, Japan
  • GSK Investigational Site
    Okayama, 700-8558, Japan
  • GSK Investigational Site
    Shizuoka, 430-8558, Japan
  • GSK Investigational Site
    Tokyo, 113-8603, Japan
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
09

References and documents

Publications

  • Yasumoto S, Shimizu M, Sato K, Kurata A, Numachi Y. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study. Brain Dev. 2016 Apr;38(4):407-13. doi: 10.1016/j.braindev.2015.10.007. Epub 2015 Oct 27. PubMed 26518979 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Feb 2014 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2011
First posted
Sep 12, 2011
Start
Sep 2011
Primary completionActual
Feb 2014
CompletionActual
Nov 2015
Results first posted
Aug 27, 2014
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01431976
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
Sep 2011
Primary completion
Feb 2014
Completion
Nov 2015
Results posted
Aug 27, 2014
Last update
Mar 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion